THOUSAND OAKS, Calif., October 1, 2025 – Amgen (NASDAQ: AMGN), one of the world’s leading biotechnology companies, announced a $650 million expansion of its U.S. manufacturing operations, a project that will create nearly 750 new jobs and strengthen the nation’s biopharmaceutical supply chain.
The investment will enhance production capacity at Amgen’s biologics facility in Juncos, Puerto Rico, while integrating advanced technologies to improve efficiency and innovation. The expansion will generate hundreds of construction jobs as well as highly skilled roles in biomanufacturing, helping to solidify Puerto Rico’s status as a premier hub for pharmaceutical manufacturing in the United States.
“This expansion underscores Amgen’s commitment to U.S. biomanufacturing and to strengthening the resilience of our global supply chain,” said Robert A. Bradway, Chairman and CEO of Amgen. “By growing our capacity to deliver innovative medicines with cutting-edge technology, we will not only better serve patients but also create high-quality jobs that reinforce America’s leadership in biotechnology.”
Puerto Rico Governor Jenniffer González Colón praised the investment, noting that Amgen’s decision highlights the island’s competitive advantages.
“This expansion not only strengthens U.S. supply chain security through reshoring, it also opens new horizons for our people as we build an innovation ecosystem that positions Puerto Rico as the strongest biopharmaceutical hub in the United States,” she said.
Economic Impact and Supply Chain Strength
According to Sebastián Negrón Reichard, Secretary of Puerto Rico’s Department of Economic Development and Commerce, Amgen’s commitment reinforces more than 60 years of expertise in the island’s pharmaceutical sector, powered by skilled talent and world-class infrastructure.
Amgen has invested more than $40 billion in manufacturing and R&D in the U.S. since 2017, supported by pro-growth tax legislation that encourages domestic innovation. Recent investments also include a $600 million science and innovation center in California, a $900 million expansion in Ohio, and a $1 billion facility in North Carolina.
About Amgen
Amgen discovers, develops, manufactures, and delivers innovative medicines to help patients fight some of the world’s toughest diseases. With more than 40 years of experience pioneering biotechnology, Amgen continues to expand its portfolio across oncology, cardiology, osteoporosis, rare diseases, and inflammatory conditions.
Recognized by Fast Company as one of the World’s Most Innovative Companies and by Forbes as one of America’s Best Large Employers, Amgen remains a global leader in science and biomanufacturing. The company is included in the Dow Jones Industrial Average® and the Nasdaq-100 Index®.
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, and Threads.
Media Contact:
George Shea
202-531-7364
media@amgen.com
Elissa Snook
609-251-1407
media@amgen.com
Investor Contact:
Adam Elinoff
805-313-9775
investors@amgen.com
